Inez de Greef | CEO, Treeway
Treeway is proud to announce that Ferrer has started a Phase 3 large-scale European trial to test the efficacy and safety of the out licensed lead product TW001, now named FNP122, for ALS. This is a huge step in the direction of bringing the first effective treatment that slows down disease progression in ALS patients to the market.
Powered by: Hyphen Projects | Let's connect: |
Book a ticket
| |||
FAQ Contact Us Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
|
Keep me informed
Download our event app
|
© Copyright 2023 by Hyphen Projects